Abstract Background Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials. which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM. who underwent vaccination from 12/17/2020 to 3/18/2021. https://www.roneverhart.com/Bauhaus-Design-Stencil/